Astrazeneca PLC (AZN): Price and Financial Metrics


Astrazeneca PLC (AZN)

Today's Latest Price: $54.92 USD

0.19 (-0.34%)

Updated Sep 30 1:59pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • With a market capitalization of $145,658,240,000, Astrazeneca Plc has a greater market value than 98.92% of US stocks.
  • With a one year PEG ratio of 671.43, Astrazeneca Plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.15% of US stocks.
  • In terms of volatility of its share price, AZN is more volatile than just 5.67% of stocks we're observing.
  • Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are AMGN, NVO, LLY, SNY, and MDT.
  • Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.
AZN Daily Price Range
AZN 52-Week Price Range

AZN Stock Price Chart Technical Analysis Charts


AZN Price/Volume Stats

Current price $54.92 52-week high $64.94
Prev. close $55.11 52-week low $36.15
Day low $54.75 Volume 2,096,976
Day high $55.45 Avg. volume 5,220,584
50-day MA $55.64 Dividend yield 1.6%
200-day MA $51.39 Market Cap 144.13B

Astrazeneca PLC (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$54.92$14.1 -75%

Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:

  • The company's compound free cash flow growth rate over the past 5.48 years comes in at -0.12%; that's greater than only 13.19% of US stocks we're applying DCF forecasting to.
  • The company has produced more trailing twelve month cash flow than 89.97% of its sector Healthcare.
  • Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 23.73% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-75%
1%-75%
2%-75%
3%-74%
4%-74%
5%-74%

DHR, TFX, ABC, ICUI, and EHC can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


AZN Latest News Stream


Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Why Investors Should Buy Moderna Instead Of Inovio

Selling pressure on Moderna (MRNA) came to an end on Sept. 8, a week after this “Neutral” rating. Investors are starting to pick out the winners from the losers, betting on the companies poised first to mass-produce a coronavirus vaccine. And although the stock tripled since the start of the...

Chris Lau on Seeking Alpha | September 29, 2020

EU Strikes Low-Cost Deal With AstraZeneca to Pay COVID-19 Vaccine Claims

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of …

Insurance Journal | September 28, 2020

Vitamin A Palmitate Market trending worldwide, growth over Forecast Period 2020-2028| Prominent Players Hospira, Banner Pharmacaps, AstraZeneca, Teva Pharmaceutical Industries, Impax Laboratories

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Vitamin A Palmitate Market which would mention How the Covid-19 is affecting the Vitamin A Palmitate Industry, Market

OpenPR | September 28, 2020

Italian firm developing AstraZeneca's COVID-19 vaccine might go public -CEO

https://www.investing.com/news/coronavirus/italian-firm-developing-astrazenecas-covid19-vaccine-might-go-public-ceo-2309006

Investing.com | September 28, 2020

Dr. Fauci just said something surprising about coronavirus vaccines and face masks

Several coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw...

BGR | September 27, 2020

Read More 'AZN' Stories Here

AZN Price Returns

1-mo -1.93%
3-mo 2.88%
6-mo 25.91%
1-year 29.30%
3-year 78.87%
5-year 106.70%
YTD 13.22%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.808 seconds.